Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Effect of Psilocybin and Ketamine on Brain Neurotransmitters, Glutamate Receptors, DNA and Rat Behavior
Adam Wojtas, Agnieszka Bysiek, Agnieszka Wawrzczak‐Bargieła, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 12, pp. 6713-6713
Open Access | Times Cited: 63

Showing 1-25 of 63 citing articles:

Monoamine Neurotransmitters Control Basic Emotions and Affect Major Depressive Disorders
Yao Jiang, Di Zou, Yumeng Li, et al.
Pharmaceuticals (2022) Vol. 15, Iss. 10, pp. 1203-1203
Open Access | Times Cited: 107
The Bright Side of Psychedelics: Latest Advances and Challenges in Neuropharmacology
Andrea Mastinu, Margrate Anyanwu, Marinella Carone, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 2, pp. 1329-1329
Open Access | Times Cited: 36
Ketamine and serotonergic psychedelics: An update on the mechanisms and biosignatures underlying rapid-acting antidepressant treatment
Jenessa N. Johnston, Bashkim Kadriu, Josh Allen, et al.
Neuropharmacology (2023) Vol. 226, pp. 109422-109422
Open Access | Times Cited: 32
Effect of psilocybin on marble burying in ICR mice: role of 5-HT1A receptors and implications for the treatment of obsessive-compulsive disorder
Sandeep Singh, Alexander Botvinnik, Orr Shahar, et al.
Translational Psychiatry (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 29
Psychedelics for acquired brain injury: a review of molecular mechanisms and therapeutic potential
Josh Allen, Shannon Dames, Claire J. Foldi, et al.
Molecular Psychiatry (2024) Vol. 29, Iss. 3, pp. 671-685
Closed Access | Times Cited: 13
Exploring DMT: Endogenous Role and Therapeutic Potential
J. Schimmelpfennig, Kamila Jankowiak-Siuda
Neuropharmacology (2025), pp. 110314-110314
Open Access | Times Cited: 1
Mice Lacking the Serotonin Transporter do not Respond to the Behavioural Effects of Psilocybin
James J Gattuso, Carey Wilson, Shanshan Li, et al.
European Journal of Pharmacology (2025), pp. 177304-177304
Closed Access | Times Cited: 1
Ketamine’s rapid antidepressant effects are mediated by Ca2+-permeable AMPA receptors
Anastasiya Zaytseva, Evelina Bouckova, McKennon J Wiles, et al.
eLife (2023) Vol. 12
Open Access | Times Cited: 18
Esketamine and Psilocybin—The Comparison of Two Mind-Altering Agents in Depression Treatment: Systematic Review
Dominika Psiuk, Emilia Nowak, Natalia Dycha, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 19, pp. 11450-11450
Open Access | Times Cited: 26
Preclinical perspectives on the mechanisms underlying the therapeutic actions of psilocybin in psychiatric disorders
Andreas B. Wulff, Charles D. Nichols, Scott M. Thompson
Neuropharmacology (2023) Vol. 231, pp. 109504-109504
Open Access | Times Cited: 14
Drug–drug interactions involving classic psychedelics: A systematic review
Andreas Halman, Geraldine Kong, Jerome Sarris, et al.
Journal of Psychopharmacology (2023) Vol. 38, Iss. 1, pp. 3-18
Open Access | Times Cited: 13
Unraveling psilocybin’s therapeutic potential: behavioral and neuroplasticity insights in Wistar-Kyoto and Wistar male rat models of treatment-resistant depression
Magdalena Kolasa, Agnieszka Nikiforuk, Agata Korlatowicz, et al.
Psychopharmacology (2024)
Open Access | Times Cited: 5
Neurochemical and Neurophysiological Effects of Intravenous Administration ofN,N-dimethyltryptamine in Rats
Nicolas G. Glynos, Emma R. Huels, Amanda Nelson, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 4
Olanzapine exposure disordered lipid metabolism, gut microbiota and behavior in zebrafish (Danio rerio)
Yawei Wang, Fu You, Zhenyi Huang, et al.
Comparative Biochemistry and Physiology Part C Toxicology & Pharmacology (2025) Vol. 289, pp. 110120-110120
Closed Access
Mushrooms, Microdosing, and Mental Illness: The Effect of Psilocybin on Neurotransmitters, Neuroinflammation, and Neuroplasticity
Daniel A Kinderlehrer
Neuropsychiatric Disease and Treatment (2025) Vol. Volume 21, pp. 141-155
Open Access
Psilocin fosters neuroplasticity in iPSC-derived human cortical neurons
Målin Schmidt, Anne Hoffrichter, Mahnaz Davoudi, et al.
(2025)
Open Access
Psilocin fosters neuroplasticity in iPSC-derived human cortical neurons
Målin Schmidt, Anne Hoffrichter, Mahnaz Davoudi, et al.
(2025)
Open Access
Coadministration of scopolamine and mGlu2 receptor negative allosteric modulator VU6001966 as a potential therapeutic approach for depression: Rat frontal cortex neurochemistry and behavior
Yana Babii, Agnieszka Pałucha-Poniewiera, Krystyna Gołembiowska, et al.
Pharmacology Biochemistry and Behavior (2025) Vol. 250, pp. 173996-173996
Closed Access
The effect of low-dose psilocybin on brain neurotransmission and rat behavior
Agnieszka Bysiek, Adam Wojtas, Izabela Szpręgiel, et al.
Progress in Neuro-Psychopharmacology and Biological Psychiatry (2025), pp. 111347-111347
Closed Access
A Comprehensive Review of the Current Status of the Cellular Neurobiology of Psychedelics
Blerida Banushi, Vince Polito
Biology (2023) Vol. 12, Iss. 11, pp. 1380-1380
Open Access | Times Cited: 12
The need for guidance in antidepressant drug development: Revisiting the role of the forced swim test and tail suspension test
Emily R. Trunnell, John F. Baines, Stephen Farghali, et al.
Regulatory Toxicology and Pharmacology (2024) Vol. 151, pp. 105666-105666
Open Access | Times Cited: 4
Epigenetic mechanisms of rapid-acting antidepressants
Antonio Inserra, Antonella Campanale, Tamim Rezai, et al.
Translational Psychiatry (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 4
Preclinical models of treatment-resistant depression: challenges and perspectives
Magdalena Kolasa, Agata Faron‐Górecka
Pharmacological Reports (2023) Vol. 75, Iss. 6, pp. 1326-1340
Open Access | Times Cited: 10
Psychedelics action and schizophrenia
Marzena Maćkowiak
Pharmacological Reports (2023) Vol. 75, Iss. 6, pp. 1350-1361
Open Access | Times Cited: 10
The evolution and ecology of psilocybin in nature
Matthew J. Meyer, Jason C. Slot
Fungal Genetics and Biology (2023) Vol. 167, pp. 103812-103812
Closed Access | Times Cited: 9
Page 1 - Next Page

Scroll to top